> ## Content Index > Fetch the complete content index at: https://bioweek.com/llms.txt > Use this file to discover other available public pages before exploring further. # Onswik Makes Weekly Insulin a Two-Horse Race, and Now the Hard Question Begins - URL: https://bioweek.com/onswik-makes-weekly-insulin-a-two-horse-race-and-now-the-hard-question-begins/ - Published: 2026-09-29T05:06:24.000Z - Updated: 2026-09-29T05:06:24.000Z - Description: Lilly's once-weekly insulin Onswik is the second FDA approval in a six-month window, after Novo's Awiqli. Both won on non-inferiority data, leaving the real question open: whether weekly dosing actually improves insulin initiation and adherence. - Author: BioWeek - Tags: Pipeline, Markets Eli Lilly [announced](https://www.prnewswire.com/news-releases/us-food-and-drug-administration-fda-approves-lillys-onswik-insulin-efsitora-alfa-gobe-a-once-weekly-basal-insulin-injection-treatment-for-adults-living-with-type-2-diabetes-302888473.html?ref=bioweek.com) on September 24, 2026 that the FDA approved Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes, to be used along with diet and exercise. It is the fourth global approval for the drug, following the EMA, Mexico's COFEPRIS, and Japan's PMDA, but it is the second such approval in the United States. Novo Nordisk's Awiqli (insulin icodec-abae) crossed the same line on March 27, 2026\. Within six months, weekly basal insulin has gone from a research bet to an actual category with two competing products in it. ### Two approvals, the same evidentiary bar Neither product won its label by beating a daily insulin. Both were approved on non-inferiority data: the FDA concluded the weekly option performs comparably to the daily standard. Onswik's case rests on the QWINT Phase 3 program, which enrolled more than 3,400 adults with type 2 diabetes. In each QWINT trial, once-weekly Onswik met the primary endpoint of non-inferior A1C reduction compared with insulin glargine U-100 or insulin degludec U-100, with an overall safety profile similar to the daily insulins studied. The two published head-to-head trials show how narrow that comparability is in practice. In [QWINT-3](https://pubmed.ncbi.nlm.nih.gov/40562047/?ref=bioweek.com), a 78-week treat-to-target study across 127 sites in nine countries, 986 adults already on basal insulin were randomized 2:1 to efsitora or degludec. Week-26 A1C fell 0.81 percentage points on efsitora versus 0.72 on degludec, an estimated treatment difference of 0.09 points with a confidence interval that grazed zero. Hypoglycemia was similarly flat: 0.84 events per patient-year for efsitora against 0.74 for degludec over the full 78 weeks, a rate ratio of 1.14 that did not reach significance. [QWINT-4](https://sah.borca.ai/papers/279469793?ref=bioweek.com) told a comparable story in patients on basal-plus-prandial regimens. Over 26 weeks at 78 clinics in seven countries, 730 participants split evenly between efsitora and glargine U-100, both layered with mealtime insulin lispro, posted nearly identical A1C reductions of 1.01 versus 1.00 percentage points. Overall hypoglycemia ran slightly higher on the weekly arm (6.6 versus 5.9 events per patient-year, rate ratio 1.11), though nocturnal events ran lower (rate ratio 0.67). In both trials, the weekly drug matched the daily drug within the noise of the data. The regulatory question is settled; the clinical question is not. ### The trade-off hiding in the once-a-week dose Efsitora is an insulin Fc-fusion protein engineered so that a single injection carries roughly a week of basal insulin, which is why the products arrive at unusual concentrations: Onswik's KwikPen at 500 units/mL and 1,000 units/mL, Awiqli at 700 U/mL. That pharmacology is the whole value proposition and the whole risk at once. Lilly says Onswik is designed to cut injections by over 300 per year versus once-daily basal insulin, and a patient switching from 365 daily injections to 52 weekly ones will feel that difference immediately. But a missed weekly dose removes a week of basal coverage, not a day of it. The long tail that makes forgiving once-daily insulin schedules tolerable is stretched, deliberately, across seven days. Real-world adherence rarely matches trial conduct, and consolidating the failure mode is not the same as solving it. The QWINT and ONWARDS trials were run under structured follow-up that real-world clinics will not replicate. Whether weekly dosing genuinely improves glycemic control at the population level, or simply trades 365 small adherence risks for 52 large ones, will only be visible in claims data years from now. ### Why the category exists at all The premise both companies are betting on is that injection frequency was a real barrier to insulin initiation and persistence, not just a survey answer. Novo's path to US approval underlines how contested that premise can be even inside the regulatory apparatus. Icodec received a Complete Response Letter from the FDA on July 10, 2024, citing requests on the manufacturing process and the type 1 indication, after a May 2024 advisory committee panel concluded the data were not sufficient to establish a positive benefit-risk in type 1 diabetes. The [approval](https://www.pharmacytimes.com/view/fda-approves-insulin-icodec-abae-first-once-weekly-basal-insulin-for-adults-with-t2d?ref=bioweek.com) that followed on March 27, 2026 was limited to adults with type 2 diabetes. Onswik's label carries the same boundary: the drug should not be used in type 1 diabetes due to increased risk of severe hypoglycemia. The market both products are chasing is enormous. Lilly notes that around one in eight Americans live with diabetes, most of them with type 2, and projects that by 2030 more than 510 million people globally will live with diabetes, 38 million of them using insulin. Even a modest share of basal insulin users moving from daily to weekly dosing would reshape a device-and-consumable market built around daily pens. ### What to watch next The first six months of this category have established that weekly basal insulin works as well as daily basal insulin under trial conditions. What remains unproven is the behavioral thesis underneath it. Prescribing patterns, real-world adherence, and any hypoglycemia divergence between the two products will answer whether once-weekly insulin was an unmet need waiting for the chemistry, or a convenience in search of a problem. Both companies now have the label. Neither has the evidence yet.